Human anti-semaphorin 4D antibody
Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
1 . A method for inhibiting semaphorin 4D (SEMA4D) interaction with its Plexin-B1 receptor in a subject in need of treatment for a SEMA4D-mediated disease or disorder, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3 comprising amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively; and wherein the VL comprises complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising amino acid sequences SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively.
2 . The method of claim 1 , wherein the VH comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 1 and/or the VL comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 5.
3 . The method of claim 1 , wherein the SEMA4D-mediated disease or disorder is an autoimmune disease or disorder or a neurodegenerative or neuroinflammatory disease or disorder.
4 . The method of claim 3 , wherein the autoimmune disease or disorder is arthritis or multiple sclerosis (MS) or an osteodegenerative disease.
5 . The method of claim 3 , wherein the neuroinflammatory disease or disorder is a is a central nervous system (CNS) or peripheral nervous system (PNS) disease or disorder.
6 . The method of claim 3 , wherein said method further comprises administering an immunosuppressive or anti-inflammatory agent.
7 . The method of claim 3 , wherein the neurodegenerative disease or disorder is Alzheimer's disease (AD), Huntington's disease (HD).
8 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof inhibits Plexin-B1 signaling.
9 . A method for treating a neurodegenerative or neuroinflammatory disease or disorder in a subject, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3 comprising amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively; and wherein the VL comprises complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising amino acid sequences SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively.
10 . The method of claim 9 , wherein the VH comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 1 and/or the VL comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 5.
11 . The method of claim 9 , wherein the antibody or antigen-binding fragment thereof inhibits binding of SEMA4D to its receptor.
12 . The method of claim 11 , wherein the receptor is Plexin-B1.
13 . The method of claim 9 , wherein the neurodegenerative or neuroinflammatory disease or disorder is a central nervous system (CNS) or peripheral nervous system (PNS) disease or disorder, AD, or HD.
14 . A method of treating a disease or disorder associated with SEMA4D pathology in a subject, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3 comprising amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively; and wherein the VL comprises complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising amino acid sequences SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively;
wherein the SEMA4D pathology is an autoimmune disease or disorder, inflammatory disease or disorder, a neuroinflammatory disease or disorder, or a neurodegenerative disease or disorder.
15 . The method of claim 14 , wherein the VH comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 1 and/or the VL comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 5.
16 . The method of claim 14 , wherein the antibody or antigen-binding fragment thereof inhibits binding of SEMA4D to its receptor.
17 . The method of claim 15 , wherein the receptor is Plexin-B1.
18 . The method of claim 14 , wherein the neurodegenerative or neuroinflammatory disease or disorder is a central nervous system (CNS) or peripheral nervous system (PNS) disease or disorder.
19 . The method of claim 14 , wherein the neurodegenerative disease or disorder is AD or HD.
20 . The method of claim 14 , comprising further administering an immunosuppressive agent or an anti-inflammatory agent.